Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025Journal of Pharmaceutical Research International

Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSarabjot Singh MakkarPAParinita ArooriLGLeela Sarmada Gaddamanugu

Discussion

Loading...

Member takes

Overview

This review evaluates dosage strategies and tolerability of CGRP-targeted therapies for migraine, suggesting flexibility in treatment application.

Key Points

  • CGRP inhibitors effectively reduce migraine frequency and are well tolerated by patients.
  • Monoclonal antibodies administered monthly show favorable tolerability with mild side effects.
  • Gepants available in oral and nasal forms provide flexibility but have moderate tolerability with some side effects.
  • CGRP-targeted therapies offer personalized treatment options but require further studies for long-term safety.

Cite This Study

Makkar et al. (2025) studied this question.

synapsesocial.com/papers/68d43c81713b0b5dfea7c19chttps://doi.org/10.9734/jpri/2025/v37i97742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025
  2. 2Mechanisms of therapeutic action of monoclonal antibodies to the calcitonin gene-related peptide (CGRP) ligand-receptor system in migraine2025
  3. 3CGRP Monoclonal Antibodies vs Gepants: Risk of Vascular Outcomes: A TriNetX Multicenter Electronic Medical Record Analysis (P10-15.012)2026
  4. 4Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data2025 · 1 citations
  5. 5Late response to anti-CGRP therapy for migraine2025